Phosphine

CASRN 7803-51-2

  • IRIS Summary (PDF) (146 pp, 20 K)
  • Status: Phosphine is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (146 pp, 20 K) last updated: 01/31/1987

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
3 x10-4 None Body weight and clinical parameters NOEL : 2.6 x10-2
mg/kg-day
100 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (146 pp, 20 K) last updated: 07/01/1995

RfC (mg/m3) System Basis PoD Composite UF Confidence
3 x10-4 Other Decreased body weight NOAEL (HEC): 2.5 x10-1
mg/m3
1000 Low

Cancer Assessment


Weight of Evidence for Cancer (PDF) (146 pp, 20 K) last updated: 09/01/1992

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on inadequate data in animals and no tumor data in humans. While phospine has not been associated with cancer in humans, there is some evidence of chromosomal damage (transient chromatid deletions, gaps and breaks, persistent chromosomal translocations). A relationship between these genetic effects and the development of cancer in humans is sometimes postulated.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (146 pp, 20 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (146 pp, 20 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.